Loading institutional data...
Loading institutional data...
Held by 978 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $17.13 today, the market must believe free cash flow compounds 4.0%/yr for a decade (off $2.1B normalized FCF).
The market's 4.0% is more optimistic than its 7-yr track record.
2-stage DCF · 1.15B shares (market data) · net debt $13.1B
mean 10.3% · volatility σ 67% · implied rate exceeded in 1/7 yrs
Central path = implied 4.0%/yr growth; shaded band = ±1σ (67%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $501M buybacks = $501M returned on $1.9B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 8 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 8 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $1.3B is below the $1.9B due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~3.3% on $14.4B of debt.
Cash of $1.3B is below short-term debt of $1.9B — relies on refinancing/operations.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.30B 100.0% | $14.74B 100.0% | $15.43B 100.0% | $16.26B 100.0% | $17.89B 100.0% | $11.95B 100.0% | $11.50B 100.0% | $11.43B 100.0% |
| Cost of Revenue | $9.29B 64.9% | $9.12B 61.8% | $8.99B 58.3% | $9.77B 60.0% | $12.31B 68.8% | $8.15B 68.2% | $7.60B 66.1% | $7.43B 65.0% |
| Gross Profit | $5.01B 35.1% | $5.62B 38.2% | $6.44B 41.7% | $6.50B 40.0% | $5.58B 31.2% | $3.80B 31.8% | $3.90B 33.9% | $4.00B 35.0% |
| Research & Development | — | — | — | — | $751.1M 4.2% | $555.1M 4.6% | $639.9M 5.6% | $704.5M 6.2% |
| Selling, General & Admin | $3.79B 26.5% | $4.10B 27.8% | $4.07B 26.4% | $4.18B 25.7% | $4.53B 25.3% | $3.34B 28.0% | $2.56B 22.3% | $2.44B 21.3% |
| Total Operating Expenses | $7.68B 53.7% | $5.61B 38.1% | $5.67B 36.8% | $4.88B 30.0% | $5.61B 31.4% | $4.01B 33.5% | $3.18B 27.7% | $3.10B 27.1% |
| Operating Income | -$2.66B -18.6% | $10.1M 0.1% | $766.2M 5.0% | $1.61B 9.9% | -$34.0M -0.2% | -$210.8M -1.8% | $715.5M 6.2% | $905.6M 7.9% |
| Interest Expense | $471.3M 3.3% | $550.0M 3.7% | $573.1M 3.7% | $592.4M 3.6% | $636.2M 3.6% | $497.8M 4.2% | $517.3M 4.5% | $542.3M 4.7% |
| Other Income (Expense), net | -$530.6M -3.7% | -$83.3M -0.6% | $9.8M 0.1% | $1.79B 11.0% | $5.8M 0.0% | -$12.6M -0.1% | -$43.8M -0.4% | -$64.9M -0.6% |
| Pretax Income | -$3.67B -25.6% | -$623.2M -4.2% | $202.9M 1.3% | $2.81B 17.3% | -$664.4M -3.7% | -$721.2M -6.0% | $154.4M 1.3% | $298.4M 2.6% |
| Income Tax Expense | -$150.1M -1.0% | $11.0M 0.1% | $148.2M 1.0% | $734.6M 4.5% | $604.7M 3.4% | -$51.3M -0.4% | $137.6M 1.2% | -$54.1M -0.5% |
| Net Income | -$3.51B -24.6% | -$634.2M -4.3% | $54.7M 0.4% | $2.08B 12.8% | -$1.27B -7.1% | -$669.9M -5.6% | $16.8M 0.1% | $352.5M 3.1% |
| Per Share | ||||||||
| EPS (Basic) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.69 |
| EPS (Diluted) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 |
| Weighted Avg Shares (Basic) | — | — | 1.20B | 1.21B | 1.21B | 601.2M | 515.7M | 514.5M |
| Weighted Avg Shares (Diluted) | — | — | 1.21B | 1.22B | 1.21B | 601.2M | 516.5M | 516.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 8-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 8878.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 65.0 | 66.1 | 68.2 | 68.8 | 60.0 | 58.3 | 61.8 | 64.9 |
| Gross Profit | 35.0 | 33.9 | 31.8 | 31.2 | 40.0 | 41.7 | 38.2 | 35.1 |
| R&D | 6.2 | 5.6 | 4.6 | 4.2 | — | — | — | — |
| SG&A | 21.3 | 22.3 | 28.0 | 25.3 | 25.7 | 26.4 | 27.8 | 26.5 |
| Operating Income | 7.9 | 6.2 | -1.8 | -0.2 | 9.9 | 5.0 | 0.1 | -18.6 |
| Income Tax | -0.5 | 1.2 | -0.4 | 3.4 | 4.5 | 1.0 | 0.1 | -1.0 |
| Net Income | 3.1 | 0.1 | -5.6 | -7.1 | 12.8 | 0.4 | -4.3 | -24.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on VTRS: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| VTRS | $19.5B | — | 241.4× | 1.4× | -3.0% | 35.1% | -24.6% | -23.9% | -12.1% | 106.6× | 978 |
Peers = companies sharing VTRS's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.